- Record quarterly revenue of $12.3M, reflecting a 25% year-over-year growth.
- Annual revenue surged by 60% to $45M, with significant improvements in product sales and security services.
- Adjusted EBITDA for Q4 2024 reached $1.8M, improving from a loss of $677K in the previous year.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) announced remarkable financial results for the fourth quarter and full year of 2024. The company achieved a record quarterly revenue of $12.3 million, marking a 25% increase compared to the same period in the previous year. For the full year, Nanalysis reached a revenue milestone of $45 million, reflecting a substantial 60% year-over-year growth.
The firm reported a significant turnaround in their quarterly performance with an Adjusted EBITDA of $1.8 million in Q4 2024, compared to a negative $677,000 in Q4 2023. On an annual basis, Adjusted EBITDA improved to $2.8 million from a loss of $7.9 million in 2023. These gains were primarily driven by a 121% rise in security services revenue to $21 million and an increase in product sales gross margin to 53% from 41%.
Despite the positive financial outcomes, the company acknowledged potential headwinds due to U.S. tariffs, which could impact product sales in the first half of 2025. However, Nanalysis has implemented mitigation strategies to counteract these challenges and remains focused on expanding margins and growing its Benchtop NMR sales.
Moreover, the company generated a positive operating cash flow of $3.3 million for the year. As part of its ongoing strategy, Nanalysis aims to continue leveraging its core competencies in portable NMR and MRI technologies for industrial and research applications, enhancing both their scientific equipment and security services business segments.
